A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis
PLOS Neglected Tropical Diseases · 19.05.2023 · 17 (5) · e0011365
DOI: 10.1371/journal.pntd.0011365 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, online erschienen am 19.05.2023. Verfasst von Nicholas O Opoku und 16 weiteren Autor:innen. Beteiligte Einrichtung: Fred Newton Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana. Hauptthemen laut MEDLINE: Onchocerciasis, Elephantiasis, Filarial, Filaricides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Background
Onchocerciasis (“river blindness”) has been targeted for elimination. New treatments that kill or permanently sterilize female worms could accelerate this process. Prior studies have shown that triple drug treatment with ivermectin plus diethylcarbamazine and albendazole (IDA) leads to prolonged clearance of microfilaremia in persons with lymphatic filariasis. We now report results from a randomized clinical trial that compared the tolerability and efficacy of IDA vs. a comparator treatment (ivermectin plus albendazole, IA) in persons with onchocerciasis. Methods and findings The study was performed in the Volta region of Ghana. Persons with microfiladermia and palpable subcutaneous nodules were pre-treated with two oral doses of ivermectin (150 μg/kg) separated by at least 6 months prior to treatment with either a single oral dose of ivermectin 150 μg/kg plus albendazole 400 mg (IA), a single oral dose of IDA (IDA1, IA plus diethylcarbamazine (DEC. 6 mg/kg) or three consecutive daily doses of IDA (IDA3). These treatments were tolerated equally well. While adverse events were common (approximately 30% overall), no severe or serious treatment-emergent adverse events were observed. Skin microfilariae were absent or present with very low densities after all three treatments through 18 months, at which time nodules were excised for histological assessment. Nodule histology was evaluated by two independent assessors who were masked regarding participant infection status or treatment assignment. Significantly lower percentages of female worms were alive and fertile in nodules recovered from study participants after IDA1 (40/261, 15.3%) and IDA3 (34/281, 12.1%) than after IA (41/180, 22.8%). This corresponds to a 40% reduction in the percentage of female worms that were alive and fertile after IDA treatments relative to results observed after the IA comparator treatment (P = 0.004). Percentages of female worms that were alive (a secondary outcome of the study) were also lower after IDA treatments (301/574, 52.4%) than after IA (127/198, 64.1%) (P = 0.004). Importantly, some comparisons (including the reduced % of fertile female worms after IDA1 vs IA treatment, which was the primary endpoint for the study) were not statistically significant when results were adjusted for intraclass correlation of worm fertility and viability for worms recovered from individual study participants.
Conclusions
Results from this pilot study suggest that IDA was well tolerated after ivermectin pretreatment. They also suggest that IDA was more effective than the comparator treatment IA for killing or sterilizing female O . volvulus worms. No other short-course oral treatment for onchocerciasis has been demonstrated to have macrofilaricidal activity. However, this first study was too small to provide conclusive results. Therefore, additional studies will be needed to confirm these promising findings.
Trial registration
The study is registered at Cinicaltrials.gov under the number NCT04188301 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Fred Newton Binka School of Public Health, University of Health and Allied Sciences, Ho, Ghana.
- Hohoe Municipal Hospital, Hohoe, Ghana.
- Institute of Medical Microbiology, Immunology and Parasitology (IMMIP), University Hospital Bonn, Bonn, Germany.
- Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri, United States of America.
- Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri.
- St. Thomas Eye Hospital, Accra, Ghana.
ORCID-Profile: Gary J Weil
Förderung
- Bill and Melinda Gates Foundation
Zitieren
APA
Opoku, N. O., Doe, F., Dubben, B., Fetcho, N., Fischer, K., Fischer, P. U., Gordor, S., Goss, C. W., Gyasi, M. E., Hoerauf, A., Hong, A. R., Kanza, E., King, C. L., Laryea, R., Lew, D., Seidu, M. A., & Weil, G. J. (2023). A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis. PLOS Neglected Tropical Diseases, 17(5), e0011365. https://doi.org/10.1371/journal.pntd.0011365
Vancouver
Opoku NO, Doe F, Dubben B, Fetcho N, Fischer K, Fischer PU, et al. A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis. PLOS Neglected Tropical Diseases. 2023;17(5):e0011365. doi:10.1371/journal.pntd.0011365
BibTeX
@article{Opoku2023,
author = {Opoku, Nicholas O and Doe, Felix and Dubben, Bettina and Fetcho, Nicole and Fischer, Kerstin and Fischer, Peter U and Gordor, Shelter and Goss, Charles W and Gyasi, Michael E and Hoerauf, Achim and Hong, Augustine R and Kanza, Eric and King, Christopher L and Laryea, Ruth and Lew, Daphne and Seidu, Mahmood A and Weil, Gary J},
title = {A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis},
journal = {PLOS Neglected Tropical Diseases},
year = {2023},
volume = {17},
number = {5},
pages = {e0011365},
doi = {10.1371/journal.pntd.0011365}
}
EUVIMED